patent/FR-2874924-A1

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2874924-A1

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fbe7b9e0223f5f7d55457f219b9c718d
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08B37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-958 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00
filingDate	2004-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2452fd52353cc89d0104a83dd0a019a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21b48ec20ba1cac9e25e8c3c7f2b826c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_843d32aa1a5d017a375bad907fc06b1f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aace9a082b19662fef7bdde1c108af59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25567a67ff7251db629aceac3b20dcf6
publicationDate	2006-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	FR-2874924-A1
titleOfInvention	BIOTINYLATED HEXADECASACCHARIDES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
abstract	The present invention relates to novel biotinylated hexadecasaccharides of the following general Formula I: wherein: Biot is a biotin derivative; R, R1 and R2, independently of one another, represent a (C1-C6) alkoxy or a -OSO3 -, - R3 represents a (C1-C6) alkoxy or -OSO3-, or R3 constitutes a -O-CH2- bridge; - Pe represents a saccharide chain, as well as their pharmaceutically acceptable salts.Medicines.
priorityDate	2004-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2814463-A1
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396881

Total number of triples: 29.